Minoxidil topique 3 % face à Finastéride topique 0,25 % + minoxidil 3 %

but was significantly superior with FMX compared with MX at 24 weeks after treatment. The mean increase at 24 weeks was 11.9 μm for FMX and 7 μm for MX (p = 0.02, according to ANOVA; Fig. 2).

Suchonwanit P, Iamsumang W, Rojhirunsakool S. Efficacy of topical combination of 0.25% finasteride and 3% minoxidil versus 3% minoxidil solution in female pattern hair loss: a randomized, double-blind, controlled study. American Journal of Clinical Dermatology 2019, DOI 10.1007/s40257-018-0387-0. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

but was significantly superior with FMX compared with MX at 24 weeks after treatment. The mean increase at 24 weeks was 11.9 μm for FMX and 7 μm for MX (p = 0.02, according to ANOVA; Fig. 2).

Suchonwanit P, Iamsumang W, Rojhirunsakool S. Efficacy of topical combination of 0.25% finasteride and 3% minoxidil versus 3% minoxidil solution in female pattern hair loss: a randomized, double-blind, controlled study. American Journal of Clinical Dermatology 2019, DOI 10.1007/s40257-018-0387-0. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

After 24 weeks of treatment, 14 (93.3%) of 15 FMX-treated participants and 12 (85.7%) of 14 MX-treated participants were rated as improved by three dermatologists using the

Suchonwanit P, Iamsumang W, Rojhirunsakool S. Efficacy of topical combination of 0.25% finasteride and 3% minoxidil versus 3% minoxidil solution in female pattern hair loss: a randomized, double-blind, controlled study. American Journal of Clinical Dermatology 2019, DOI 10.1007/s40257-018-0387-0. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

After 24 weeks of treatment, 14 (93.3%) of 15 FMX-treated participants and 12 (85.7%) of 14 MX-treated participants were rated as improved by three dermatologists using the

Suchonwanit P, Iamsumang W, Rojhirunsakool S. Efficacy of topical combination of 0.25% finasteride and 3% minoxidil versus 3% minoxidil solution in female pattern hair loss: a randomized, double-blind, controlled study. American Journal of Clinical Dermatology 2019, DOI 10.1007/s40257-018-0387-0. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

investigators. In total, 14 (93.3%) of 15 participants in the FMX group and 13 (92.9%) of 14 in the MX group reported improvement in their condition via self-evaluation on a

Suchonwanit P, Iamsumang W, Rojhirunsakool S. Efficacy of topical combination of 0.25% finasteride and 3% minoxidil versus 3% minoxidil solution in female pattern hair loss: a randomized, double-blind, controlled study. American Journal of Clinical Dermatology 2019, DOI 10.1007/s40257-018-0387-0. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

investigators. In total, 14 (93.3%) of 15 participants in the FMX group and 13 (92.9%) of 14 in the MX group reported improvement in their condition via self-evaluation on a

Suchonwanit P, Iamsumang W, Rojhirunsakool S. Efficacy of topical combination of 0.25% finasteride and 3% minoxidil versus 3% minoxidil solution in female pattern hair loss: a randomized, double-blind, controlled study. American Journal of Clinical Dermatology 2019, DOI 10.1007/s40257-018-0387-0. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Minimal local side effects were reported, but this did not differ significantly between the groups. Two patients from each group reported pruritus, and one patient in the MX

Suchonwanit P, Iamsumang W, Rojhirunsakool S. Efficacy of topical combination of 0.25% finasteride and 3% minoxidil versus 3% minoxidil solution in female pattern hair loss: a randomized, double-blind, controlled study. American Journal of Clinical Dermatology 2019, DOI 10.1007/s40257-018-0387-0. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Minimal local side effects were reported, but this did not differ significantly between the groups. Two patients from each group reported pruritus, and one patient in the MX

Suchonwanit P, Iamsumang W, Rojhirunsakool S. Efficacy of topical combination of 0.25% finasteride and 3% minoxidil versus 3% minoxidil solution in female pattern hair loss: a randomized, double-blind, controlled study. American Journal of Clinical Dermatology 2019, DOI 10.1007/s40257-018-0387-0. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

The mean change from baseline in total hair density at week 24 was 61.84 ± 15.65 hairs/cm2 in the FMX group and 34.88 ± 10.24 hairs/cm2 in the MX group, with an amount of superiority at about 27 hairs/cm2.

Citation complémentaire (inclusion)

FMXGroup MX Group N = 19 N = 18 39.3 (11.9) 44.4 (12.5) 32.3 (2.7) 35.1 (2.7) 8.1 (5.5) 10 (8) 4 (21.1) 4 (22.2) 8 (42.1) 10 (55.6) 7 (36.8) 4 (22.2) 100.3 (16.2) 105 (18.4) 47 (10) 49 (10) 511 483 63-1,273 257-978

Citation complémentaire (methode)

Table 1 Demographics and baseline characteristics

Citation complémentaire (significativite)

Changes from baseline to week 24 in hair density and hair diameter between FMX and MX group showed a significant difference (P = 0.003 and 0.04, respectively).

Suchonwanit P, Srisuwanwattana P, Chalermroj N et al.. A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil versus 3% minoxidil solution in the treatment of male androgenetic alopecia. Journal of the European Academy of Dermatology and Venereology 2018, DOI 10.1111/jdv.15171. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

The mean change from baseline in total hair density at week 24 was 61.84 ± 15.65 hairs/cm2 in the FMX group and 34.88 ± 10.24 hairs/cm2 in the MX group, with an amount of superiority at about 27 hairs/cm2.

Citation complémentaire (inclusion)

FMXGroup MX Group N = 19 N = 18 39.3 (11.9) 44.4 (12.5) 32.3 (2.7) 35.1 (2.7) 8.1 (5.5) 10 (8) 4 (21.1) 4 (22.2) 8 (42.1) 10 (55.6) 7 (36.8) 4 (22.2) 100.3 (16.2) 105 (18.4) 47 (10) 49 (10) 511 483 63-1,273 257-978

Citation complémentaire (methode)

Table 1 Demographics and baseline characteristics

Citation complémentaire (significativite)

Changes from baseline to week 24 in hair density and hair diameter between FMX and MX group showed a significant difference (P = 0.003 and 0.04, respectively).

Suchonwanit P, Srisuwanwattana P, Chalermroj N et al.. A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil versus 3% minoxidil solution in the treatment of male androgenetic alopecia. Journal of the European Academy of Dermatology and Venereology 2018, DOI 10.1111/jdv.15171. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

The mean change from baseline in hair diameter at week 24 was 17 ± 5.24 μm in the FMX group and 13 ± 4.15 μm in the MX group, with an amount of superiority at 4 μm.

Citation complémentaire (inclusion)

FMXGroup MX Group N = 19 N = 18 39.3 (11.9) 44.4 (12.5) 32.3 (2.7) 35.1 (2.7) 8.1 (5.5) 10 (8) 4 (21.1) 4 (22.2) 8 (42.1) 10 (55.6) 7 (36.8) 4 (22.2) 100.3 (16.2) 105 (18.4) 47 (10) 49 (10) 511 483 63-1,273 257-978

Citation complémentaire (methode)

Table 1 Demographics and baseline characteristics

Citation complémentaire (significativite)

Changes from baseline to week 24 in hair density and hair diameter between FMX and MX group showed a significant difference (P = 0.003 and 0.04, respectively).

Suchonwanit P, Srisuwanwattana P, Chalermroj N et al.. A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil versus 3% minoxidil solution in the treatment of male androgenetic alopecia. Journal of the European Academy of Dermatology and Venereology 2018, DOI 10.1111/jdv.15171. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

The mean change from baseline in hair diameter at week 24 was 17 ± 5.24 μm in the FMX group and 13 ± 4.15 μm in the MX group, with an amount of superiority at 4 μm.

Citation complémentaire (inclusion)

FMXGroup MX Group N = 19 N = 18 39.3 (11.9) 44.4 (12.5) 32.3 (2.7) 35.1 (2.7) 8.1 (5.5) 10 (8) 4 (21.1) 4 (22.2) 8 (42.1) 10 (55.6) 7 (36.8) 4 (22.2) 100.3 (16.2) 105 (18.4) 47 (10) 49 (10) 511 483 63-1,273 257-978

Citation complémentaire (methode)

Table 1 Demographics and baseline characteristics

Citation complémentaire (significativite)

Changes from baseline to week 24 in hair density and hair diameter between FMX and MX group showed a significant difference (P = 0.003 and 0.04, respectively).

Suchonwanit P, Srisuwanwattana P, Chalermroj N et al.. A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil versus 3% minoxidil solution in the treatment of male androgenetic alopecia. Journal of the European Academy of Dermatology and Venereology 2018, DOI 10.1111/jdv.15171. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Global photographic assessment by investigators: There was substantial agreement on individual scores rated by a panel of 3 dermatologists (Fleiss’ Kappa = 0.62). FMX showed significant superiority over MX in promoting hair growth at week 24 (P = 0.026) (Fig. 2(a)). About two-thirds of FMX-treated subjects, accounting for 63.1%, were rated as showing marked improvement, compared to 22.2% of MX-treated subjects.

Suchonwanit P, Srisuwanwattana P, Chalermroj N et al.. A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil versus 3% minoxidil solution in the treatment of male androgenetic alopecia. Journal of the European Academy of Dermatology and Venereology 2018, DOI 10.1111/jdv.15171. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Global photographic assessment by investigators: There was substantial agreement on individual scores rated by a panel of 3 dermatologists (Fleiss’ Kappa = 0.62). FMX showed significant superiority over MX in promoting hair growth at week 24 (P = 0.026) (Fig. 2(a)). About two-thirds of FMX-treated subjects, accounting for 63.1%, were rated as showing marked improvement, compared to 22.2% of MX-treated subjects.

Suchonwanit P, Srisuwanwattana P, Chalermroj N et al.. A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil versus 3% minoxidil solution in the treatment of male androgenetic alopecia. Journal of the European Academy of Dermatology and Venereology 2018, DOI 10.1111/jdv.15171. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Global photographic assessment by patients: FMX also showed significant superiority over MX in promoting hair growth at week 24 (P = 0.032) (Fig. 2(b)). Similarly, 52.6% of FMX-treated subjects were rated as showing marked improvement, compared to 16.7% of MX-treated subjects.

Suchonwanit P, Srisuwanwattana P, Chalermroj N et al.. A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil versus 3% minoxidil solution in the treatment of male androgenetic alopecia. Journal of the European Academy of Dermatology and Venereology 2018, DOI 10.1111/jdv.15171. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Global photographic assessment by patients: FMX also showed significant superiority over MX in promoting hair growth at week 24 (P = 0.032) (Fig. 2(b)). Similarly, 52.6% of FMX-treated subjects were rated as showing marked improvement, compared to 16.7% of MX-treated subjects.

Suchonwanit P, Srisuwanwattana P, Chalermroj N et al.. A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil versus 3% minoxidil solution in the treatment of male androgenetic alopecia. Journal of the European Academy of Dermatology and Venereology 2018, DOI 10.1111/jdv.15171. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

There were neither serious adverse events nor sexual problems reported in both groups. One patient in the MX group complained of headache, possibly related to study medication. A dry and flaky scalp was developed in 3 patients and 2 patients in the FMX and MX group, respectively. Two patients in each group also experienced scalp pruritus. All adverse effects were rated mild in severity, and there were no differences between treatment groups.

Suchonwanit P, Srisuwanwattana P, Chalermroj N et al.. A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil versus 3% minoxidil solution in the treatment of male androgenetic alopecia. Journal of the European Academy of Dermatology and Venereology 2018, DOI 10.1111/jdv.15171. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

There were neither serious adverse events nor sexual problems reported in both groups. One patient in the MX group complained of headache, possibly related to study medication. A dry and flaky scalp was developed in 3 patients and 2 patients in the FMX and MX group, respectively. Two patients in each group also experienced scalp pruritus. All adverse effects were rated mild in severity, and there were no differences between treatment groups.

Suchonwanit P, Srisuwanwattana P, Chalermroj N et al.. A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil versus 3% minoxidil solution in the treatment of male androgenetic alopecia. Journal of the European Academy of Dermatology and Venereology 2018, DOI 10.1111/jdv.15171. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

There were neither serious adverse events nor sexual problems reported in both groups. One patient in the MX group complained of headache, possibly related to study medication. A dry and flaky scalp was developed in 3 patients and 2 patients in the FMX and MX group, respectively. Two patients in each group also experienced scalp pruritus. All adverse effects were rated mild in severity, and there were no differences between treatment groups.

Suchonwanit P, Srisuwanwattana P, Chalermroj N et al.. A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil versus 3% minoxidil solution in the treatment of male androgenetic alopecia. Journal of the European Academy of Dermatology and Venereology 2018, DOI 10.1111/jdv.15171. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

There were neither serious adverse events nor sexual problems reported in both groups. One patient in the MX group complained of headache, possibly related to study medication. A dry and flaky scalp was developed in 3 patients and 2 patients in the FMX and MX group, respectively. Two patients in each group also experienced scalp pruritus. All adverse effects were rated mild in severity, and there were no differences between treatment groups.

Suchonwanit P, Srisuwanwattana P, Chalermroj N et al.. A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil versus 3% minoxidil solution in the treatment of male androgenetic alopecia. Journal of the European Academy of Dermatology and Venereology 2018, DOI 10.1111/jdv.15171. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

There were neither serious adverse events nor sexual problems reported in both groups. One patient in the MX group complained of headache, possibly related to study medication. A dry and flaky scalp was developed in 3 patients and 2 patients in the FMX and MX group, respectively. Two patients in each group also experienced scalp pruritus. All adverse effects were rated mild in severity, and there were no differences between treatment groups.

Suchonwanit P, Srisuwanwattana P, Chalermroj N et al.. A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil versus 3% minoxidil solution in the treatment of male androgenetic alopecia. Journal of the European Academy of Dermatology and Venereology 2018, DOI 10.1111/jdv.15171. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

There were neither serious adverse events nor sexual problems reported in both groups. One patient in the MX group complained of headache, possibly related to study medication. A dry and flaky scalp was developed in 3 patients and 2 patients in the FMX and MX group, respectively. Two patients in each group also experienced scalp pruritus. All adverse effects were rated mild in severity, and there were no differences between treatment groups.

Suchonwanit P, Srisuwanwattana P, Chalermroj N et al.. A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil versus 3% minoxidil solution in the treatment of male androgenetic alopecia. Journal of the European Academy of Dermatology and Venereology 2018, DOI 10.1111/jdv.15171. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

The median percent decrease from baseline in plasma DHT levels at week 24 was 5.7% in the FMX group and 7.4% in the MX group, without a significant difference between groups (P = 0.92)

Citation complémentaire (inclusion)

FMXGroup MX Group N = 19 N = 18 39.3 (11.9) 44.4 (12.5) 32.3 (2.7) 35.1 (2.7) 8.1 (5.5) 10 (8) 4 (21.1) 4 (22.2) 8 (42.1) 10 (55.6) 7 (36.8) 4 (22.2) 100.3 (16.2) 105 (18.4) 47 (10) 49 (10) 511 483 63-1,273 257-978

Citation complémentaire (methode)

Table 1 Demographics and baseline characteristics

Suchonwanit P, Srisuwanwattana P, Chalermroj N et al.. A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil versus 3% minoxidil solution in the treatment of male androgenetic alopecia. Journal of the European Academy of Dermatology and Venereology 2018, DOI 10.1111/jdv.15171. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

The median percent decrease from baseline in plasma DHT levels at week 24 was 5.7% in the FMX group and 7.4% in the MX group, without a significant difference between groups (P = 0.92)

Citation complémentaire (inclusion)

FMXGroup MX Group N = 19 N = 18 39.3 (11.9) 44.4 (12.5) 32.3 (2.7) 35.1 (2.7) 8.1 (5.5) 10 (8) 4 (21.1) 4 (22.2) 8 (42.1) 10 (55.6) 7 (36.8) 4 (22.2) 100.3 (16.2) 105 (18.4) 47 (10) 49 (10) 511 483 63-1,273 257-978

Citation complémentaire (methode)

Table 1 Demographics and baseline characteristics

Suchonwanit P, Srisuwanwattana P, Chalermroj N et al.. A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil versus 3% minoxidil solution in the treatment of male androgenetic alopecia. Journal of the European Academy of Dermatology and Venereology 2018, DOI 10.1111/jdv.15171. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).